Form S-8 Oruka Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Stifel Reiterates Buy Rating on Oruka Therapeutics (ORKA)
March 7, 2025 7:41 AM ESTStifel analyst Alex Thompson reiterated a Buy rating and $49.00 price target on Oruka Therapeutics (NASDAQ: ORKA)
The analyst comments "We are reiterating our Buy rating following ORKA's 4Q24 update. We think ORKA is well-positioned to drive continued innovation in the psoriasis market (and beyond)... More
